After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
BIOA belongs to the Healthcare sector of the NASDAQ while operating in the Drug Manufacturers – Specialty & Generic industry. The current market capitalization of BioAge Labs Inc is $151.65M. A total of 0.52 million shares were traded on the day, compared to an average of 243.65K shares.
In the most recent transaction, Barton Shane bought 2,632 shares of BIOA for 18.00 per share on Sep 27 ’24. After the transaction, the Principal Accounting Officer now owns 2,632 company shares. In a previous transaction on Oct 01 ’24, Pande Vijay Satyanand bought 126,793 shares at 19.73 per share. BIOA shares that Director owns now total 1,026,793.
Among the insiders who bought shares, Pande Vijay Satyanand acquired of 67,096 shares on Oct 02 ’24 at a per-share price of $19.73. This resulted in the Director holding 1,093,889 shares of BIOA after the transaction. In another insider transaction, Pande Vijay Satyanand bought 25,306 shares at $19.90 per share on Oct 03 ’24. Company shares held by the Director now total 1,119,195.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, BIOA has a high of $26.62 and a low of $2.88.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BIOA is Buy with a score of 2.75.
